Dietary flavonoids in cancer therapy and prevention: Substrates and inhibitors of cytochrome P450 CYP1 enzymes

Pharmacology and Therapeutics

Volumn 126, Issue 1, 2010, Pages 9-20

  Androutsopoulos, Vasilis P ^a   Papakyriakou, Athanasios ^b   Vourloumis, Dionisios ^b   Tsatsakis, Aristidis M ^a   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

Chemoprevention; CYP1 enzymes; Flavonoids; Inhibition; Metabolism

Indexed keywords

2' NITROFLAVONE; 5,7 DIMETHOXYFLAVONE; AMINOFLAVONE; APIGENIN; CANCER VACCINE; CHRYSIN; CYTOCHROME P450; CYTOCHROME P450 1; CYTOCHROME P450 1B1 VACCINE; CYTOTOXIC AGENT; DIOSMETIN; DIOSMIN; ETHOXYRESORUFIN; EUPATORIN; FLAVONOID; FLAVONOID GLYCOSIDE; LUTEOLIN; NARINGENIN; PICEATTANOL; PLANT MEDICINAL PRODUCT; QUERCETIN; SCUTELLAREIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER THERAPY; CLINICAL TRIAL; DIETARY INTAKE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; FOOD DRUG INTERACTION; HUMAN; HYDROPHILICITY; HYDROXYLATION; INTESTINE FUNCTION; LIGAND BINDING; LIPOPHILICITY; LIVER METABOLISM; MITOSIS INHIBITION; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; ORANGE JUICE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; DIETARY SUPPLEMENTS; FLAVONOIDS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 77949275110     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.01.009     Document Type: Review

References (94)

1. Andres A., Donovan S.M., and Kuhlenschmidt M.S. Soy isoflavones and virus infections. J Nutr Biochem 20 (2009) 563-569
2. Androutsopoulos V., Arroo R.R., Hall J.F., Surichan S., and Potter G.A. Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1 mediated metabolism. Breast Cancer Res 10 (2008) R39
3. Androutsopoulos V., Arroo R.R., Wilsher N., and Potter G.A. Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450. Cancer Lett 274 (2009) 54-60
4. Androutsopoulos V.P., Li N., and Arroo R.R. The methoxylated flavones eupatorin and cirsiliol induce CYP1 enzyme expression in MCF7 cells. J Nat Prod 72 (2009) 1390-1394
5. Androutsopoulos V.P., Mahale S., Arroo R.R., and Potter G.A. Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 cells, due to CYP1 activation. Oncol Rep 21 (2009) 1525-1528
6. Androutsopoulos V.P., Ruparelia K., Arroo R.R., Tsatsakis A.M., and Spandidos D.A. CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology 264 (2009) 162-170
7. Androutsopoulos V.P., Tsatsakis A.M., and Spandidos D.A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 9 (2009) 187
8. Arroo R.R.J., Androutsopoulos V., Beresford K., Ruparelia K., Surichan S., Wilsher N., et al. Phytoestrogens as natural prodrugs in cancer prevention: dietary flavonoids. Phytochem Rev 8 (2009) 375-386
9. Arroo R.R.J., Androutsopoulos V., Patel A., Surichan S., Wilsher N., and Potter G.A. Phytoestrogens as natural prodrugs in cancer prevention: a novel concept. Phytochem Rev 7 (2008) 431-443
10. Atherton K.M., Mutch E., and Ford D. Metabolism of the soyabean isoflavone daidzein by CYP1A2 and the extra-hepatic CYPs 1A1 and 1B1 affects biological activity. Biochem Pharmacol 72 (2006) 624-631
11. Birt D.F., Mitchell D., Gold B., Pour P., and Pinch H.C. Inhibition of ultraviolet light skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Res 17 (1997) 85-91
12. Birt D.F., Hendrich S., and Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90 (2001) 157-177
13. Boersma M.G., van der Woude H., Bogaards J., Boeren S., Vervoort J., Cnubben N.H.P., et al. Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem Res Toxicol 15 (2002) 662-670
14. Breinholt V.M., Offord E.A., Brouwer C., Nielsen S.E., Brøsen K., and Friedberg T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol 40 (2002) 609-616
15. Breinholt V.M., Rasmussen S.E., Brøsen K., and Friedberg T.H. In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s. Pharmacol Toxicol 93 (2003) 14-22
16. Cárdenas M.G., Zotta E., Marder M., and Roguin L.P. In vitro induction of apoptosis and in vivo effects of a flavone nitroderivative in murine mammary adenocarcinoma cells. Int J Cancer 125 (2009) 222-228
17. Chan H.Y., and Leung L.K. A potential protective mechanism of soya isoflavones against 7, 12-dimethylbenz[a]anthracene tumour initiation. Br J Nutr 90 (2003) 457-465
18. Chang T.K.H., Chen J., and Yeung E.Y.H. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. Toxicol Appl Pharmacol 213 (2006) 18-26
19. Chan H.Y., Wang H., and Leung L.K. The red clover (Trifolium pratense) isoflavone biochanin A modulates the biotransformation pathways of 7, 12-dimethylbenz[a]anthracene. Br J Nutr 90 (2003) 87-92
20. Chaudhary A., and Willet K.L. Inhibition of human cytochrome CYP1 enzymes by flavonoids of St John's wort. Toxicology 217 (2006) 194-205
21. Choi E.J., and Kim T. Daidzein modulates induction of hepatic CYP1A1, 1B1 and AhR by 7, 12-dimethylbenz[a]anthracene in mice. Arch Pharm Res 31 (2008) 1115-1119
22. Chung H.J., Choi Y.H., Kim S.H., and Lee M.G. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol 58 (2006) 449-457
23. Ciolino H.P., Daschner P.J., and Yeh G.C. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem J 340 (1999) 715-722
24. Ciolino H.P., and Yeh G.C. The flavonoid galangin in an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br J Cancer 79 (1999) 1340-1346
25. Ciolino H.P., Wang T.T., and Yeh G.C. Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Cancer Res 56 (1998) 197-206
26. Dai R., Zhai S., Wei X., Pincus M.R., Vestal R.E., and Friedman F.K. Inhibition of human cytochrome P450 1A2 by flavones: a molecular modeling study. J Protein Chem 17 (1998) 643-650
27. Don M.J., Lewis D.F., Wang S.Y., Tsai M.W., and Ueng Y.F. Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2 and CYP1B1. Bioorg Med Chem Lett 13 (2003) 2535-2538
28. Doostdar H., Burke M.D., and Mayer R.T. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144 (2000) 31-38
29. Erlund I., Kosonen T., Alfthan G., Mäenpää J., Perttunen K., Kenraali J., et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56 (2000) 545-553
30. Erlund I., Meririnne E., Alfthan G., and Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperitin in humans after ingestion of orange juice and grapefruit juice. J Nutr 131 (2001) 235-241
31. Fuhr U., Klittich K., and Staib A.H. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharm 35 (1993) 431-436
32. Galijatovic A., Otake Y., Walle U.K., and Walle T. Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica 29 (1999) 1241-1256
33. Gradolatto A., Canivenc-Lavier M.C., Basly J.P., Siess M.H., and Teyssier C. Metabolism of apigenin by rat liver phase I and phase II enzymes and by isolated perfused rat liver. Drug Metab Dispos 32 (2004) 58-65
34. Gribben J.G., Ryan D.P., Boyajian R., Urban R.G., Hedley M.L., Beach K., et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 12 (2005) 4430-4436
35. Hadjokas N.E., Dai R., Friedman F.K., Spence M.J., Cusack B.J., Vestal R.E., et al. Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells. Br J Pharmacol 136 (2002) 347-352
36. Helsby N.A., Chipman J.K., Gescher A., and Kerr D. Inhibition of mouse and human CYP 1A- and 2E1-dependent substrate metabolism by the isoflavonoids genistein and equol. Food Chem Toxicol 36 (1998) 375-382
37. Hollman P.C.H., and Katan M.B. Bioavailability and health effects of dietary flavonols in man. Arch Toxicol Suppl 20 (1998) 237-248
38. Hu M., Krausz K., Chen J., Ge X., Li J., Gelboin H.L., et al. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab Dispos 31 (2003) 924-931
39. Iori F., da Fonseca R., Ramos M.J., and Menziani M.C. Theoretical quantitative structure-activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorg Med Chem 13 (2005) 4366-4374
40. Jin N.Z., Zhu Y.P., Zhou J.W., Mao L., Zhao R.C., Fang T.H., et al. Preventive effects of quercetin against benzo[a]pyrene-induced DNA damages and pulmonary precancerous pathologic changes in mice. Basic Clin Pharmacol Toxicol 98 (2006) 593-598
41. Kim H.J., Lee S.B., Park S.K., Kim H.M., Park Y.I., and Dong M.S. Effects of hydroxyl group numbers on the B-ring of 5, 7-dihydroxyflavones on the differential inhibition of human CYP 1A and CYP1B1 enzymes. Arch Pharm Res 28 (2005) 1114-1121
42. Lamartiniere C.A., Moore J., Holland M., and Barnes S. Neonatal genistein chemoprevents mammary cancer. Proc Soc Biol Med 208 (1995) 120-123
43. Lautraite S., Musonda A.C., Doehmer J., Edwards G.O., and Chipman J.K. Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1. Mutagenesis 17 (2002) 45-53
44. Leung H.Y., Wang Y., Chan H.Y., and Leung L.K. Developing a high-throughput system for the screening of cytochrome P450 1A1-inhibitory polyphenols. Toxicol in vitro 21 (2007) 996-1002
45. Lewis D.F.V., Gillam E.M.J., Everett S.A., and Shimada T. Molecular modeling of human CYP1B1 substrate interactions and investigation of allelic variant effects on metabolism. Chem Biol Interact 145 (2003) 281-295
46. Lewis D.F., Lake B.G., and Dickins M. Quantitative structure-activity relationships within a homologous series of 7-alkoxyresorufins exhibiting activity towards CYP1A and CYP2B enzymes: molecular modeling studies on key members of the resorufin series with CYP2C5-derived models of human CYP1A1, CYP1A2, CYP2B6 and CYP3A4. Xenobiotica 34 (2004) 501-513
47. Lewis D.F.V., Lake B.G., George S.G., Dickins M., Eddershaw P.J., Tarbit M.H., et al. Molecular modeling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology 139 (1999) 53-79
48. Lewis B.C., Mackenzie P.I., and Miners J.O. Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis. Arch Biochem Biophys 468 (2007) 58-69
49. Li D.H., Yee J.A., McGuire M.H., Murphy P.A., and Yan L. Soybean isoflavones reduce experimental metastasis in mice. J Nutr 129 (1999) 1075-1078
50. Liggins J., Bluck L.J., Runswick S., Atkinson C., Coward W.A., and Bingham S.A. Daidzein and genistein content of fruits and nuts. J Nutr Biochem 11 (2000) 326-331
51. Liu J., Ericksen S.S., Sivaneri M., Besspiata D., Fisher C.W., and Szklarz G.D. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Arch Biochem Biophys 424 (2004) 33-43
52. Liu J., Ericksen S.S., Sivaneri M., Besspiata D., Fisher C.W., and Szklarz G.D. Characterization of substrate binding to cytochrome P450 1A1 using molecular modeling and kinetic analyses: case of residue 382. Drug Metab Dispos 31 (2003) 412-420
53. Loaiza-Pérez A.I., Kenney S., Boswell J., Hollingshead M., Alley M.C., Hose C., et al. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 3 (2004) 715-725
54. Lyseng-Williamson K.A., and Perry C.M. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 63 (2003) 71-100
55. McFadyen M.C., Melwin W.T., and Murray G.I. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 3 (2004) 363-371
56. McFadyen M.C., and Murray G.I. Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol 2 (2005) 259-263
57. Mitropoulou T.N., Tzanakakis G.N., Nikitovic D., Tsatsakis A., and Karamanos N.K. In vitro effects of genistein on the synthesis and distribution of glycosaminoglycans/proteoglycans by estrogen receptor-positive and -negative human breast cancer epithelial cells. Anticancer Res 22 (2002) 2841-2846
58. Murota K., and Terao J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys 417 (2003) 12-17
59. Murray G.I., Taylor V.E., McKay J.A., Weaver R.J., Ewen S.W., Melvin W.T., et al. The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J Pathol 177 (1995) 147-152
60. Murray G.I., Taylor M.C., McFadyen M.C., McKay J.A., Greenlee W.F., Burke M.D., et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57 (1997) 3026-3031
61. Nikitovic D., Tsatsakis A.M., Karamanos N.K., and Tzanakakis G.N. The effects of genistein on the synthesis and distribution of glycosaminoglycans/proteoglycans by two osteosarcoma cell lines depends on tyrosine kinase and the estrogen receptor density. Anticancer Res 23 (2003) 459-464
62. Otake Y., and Walle T. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metab Dispos 30 (2002) 103-105
63. Otake Y., Hsieh F., and Walle T. Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes. Drug Metab Dispos 30 (2002) 576-581
64. Pastrakuljic A., Tang B.K., Roberts E.A., and Kalow W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 53 (1997) 531-538
65. Patterson L.H., and Murray G.I. Tumor cytochrome P450 and drug activation. Curr Pharm Des 15 (2002) 1335-1347
66. Paysant J., Sansilvestri-Morel P., Bouskela E., and Verbeuren T.J. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol 27 (2008) 81-85
67. Peng W.X., Li H.D., and Zhou H.H. Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. Eur J Clin Pharmacol 59 (2003) 237-241
68. Peterson S., Lampe J.W., Bammler T.K., Gross-Steinmeyer K., and Eaton D.L. Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. Food Chem Toxicol 44 (2006) 1474-1484
69. Phillips R.M. Prospects for bioreductive drug development. Expert Opin Investig Drugs 6 (1998) 905-928
70. Potter G.A., Patterson L.H., Wanogho E., Perry P.J., Butler P.C., Ijac T., et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86 (2002) 774-778
71. Rathee P., Chaudhary H., Rathee S., Rathee D., Kumar V., and Kohli K. Mechanism of action of flavonoids as anti-inflammatory agents: a review. Inflamm Allergy Drug Targets 8 (2009) 229-235
72. Roberts D.W., Doerge D.R., Churchwell M.I., Gamboa da Costa G., Marques M.M., and Tolleson W.H. Inhibition of extrahepatic human cytochrome P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pretense (red clover). J Agric Food Chem 52 (2004) 6623-6632
73. Sansen S., Yano J.K., Reynald R.L., Schoch G.A., Griffin K.J., Stout C.D., et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282 (2007) 14348-14355
74. Scalbert A., and Williamson G. Dietary intake and bioavailability of dietary polyphenols. J Nutr 130 (2000) 2073S-2085S
75. Schwarz D., and Roots I. In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1. Biochem Biophys Res Commun 303 (2003) 902-907
76. Schwarz D., Kisselev P., and Roots I. St John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7, 8-dihydrodiol by human CYP1A1. Cancer Res 63 (2003) 8062-8068
77. Schwarz D., Kisselev P., and Roots I. CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin. Eur J Cancer 41 (2005) 151-158
78. Shimada T., and Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 95 (2004) 1-6
79. Siess M.H., Leclerc J., Canivenc-Lavier M.C., Rat P., and Suschetet M. Heterogeneous effects of natural flavonoids on monooxygenase activities in human and rat liver microsomes. Toxicol Appl Pharmacol 130 (1995) 73-78
80. Silva I.D., Rodrigues A.S., Gaspar J., Maia R., Laires A., and Rueff J. Involvement of rat cytochrome 1A1 in the biotransformation of kaempferol to quercetin: relevance to the genotoxicity of kaempferol. Mutagenesis 12 (1997) 383-390
81. Tanaka T., Makita H., Kawabata K., Mori H., Kakumoto M., Satoh K., et al. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids diosmin and hesperidin. Carcinogenesis 18 (1997) 957-965
82. Vaouzour D., Vafeiadou K., Rodriguez-Mateos A., Rendeiro C., and Spencer J.P. The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr 3 (2008) 115-126
83. Walle T. Absorption and metabolism of flavonoids. Free Rad Biol Med 36 (2004) 829-837
84. Walle U.K., and Walle T. Bioavailable flavonoids: cytochrome P450-mediated metabolism of methoxyflavones. Drug Metab Dispos 35 (2007) 1985-1989
85. Walle T., Otake Y., Brubaker J.A., Walle U.K., and Halushka P.V. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol 51 (2001) 143-146
86. Walle T., Walle U.K., and Halushka P.V. Carbon dioxide is the major metabolite of quercetin in humans. J Nutr 131 (2001) 2648-2652
87. Walle T., Ta N., Kawamori T., Wen X., Tsuji P.A., and Walle U.K. Cancer chemopreventive properties of orally bioavailable flavonoids-methylated versus unmethylated flavones. Biochem Pharmacol 73 (2007) 1288-1296
88. Wei H.C., Bowen R., Zhang X.S., and Lebwohl M. Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis 19 (1998) 1509-1514
89. Wen X., and Walle T. Preferential induction of CYP1B1 by benzo[a]pyrene in human oral epithelial cells: impact on DNA adduct formation and prevention by polyphenols. Carcinogenesis 26 (2005) 1774-1781
90. Wen X., and Walle T. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab Dispos 34 (2006) 1786-1792
91. Wen X., Walle U.K., and Walle T. 5, 7-Dimethoxyflavone downregulates CYP1A1 expression and benzo[a]pyrene-induced DNA binding in Hep G2 cells. Carcinogenesis 26 (2005) 803-809
92. Williams P.A., Cosme J., Ward A., Angove H.C., Matak Vinkovic D., et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424 (2003) 464-468
93. Zhai S., Dai R., Friedman F.K., and Vestal R.E. Comparative inhibition of human cytochrome P450 1A1 and 1A2 by flavonoids. Drug Metab Dispos 26 (1998) 989-992
94. Zhai S., Dai R., Wei X., Friedman F.K., and Vestal R.E. Inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes. Life Sci 63 (1998) 119-123